Madrigal Pharmaceuticals (0JXI) Share Forecast & Price Target
0JXI Analyst Ratings
Strong Buy
8Buy1Hold0Sell
Based on 9 analysts giving stock ratings to Madrigal Pharmaceuticals in the past 3 months
0JXI Stock 12 Month Forecast
Average Price Target
$686.78▲(60.26% Upside)Based on 9 Wall Street analysts offering 12 month price targets for Madrigal Pharmaceuticals in the last 3 months. The average price target is $686.78 with a high forecast of $962.00 and a low forecast of $533.00. The average price target represents a 60.26% change from the last price of $428.53.
Past 12 Months12 Month ForecastDec2025Sep2026
High$962.00
Average$686.78
Low$533.00
Highest Price TargetHighest$962.00Average Price Target$686.78Lowest Price TargetLowest$533.00
Detailed List of Analyst Forecasts
Analyst Type
Ranks
Analyst Rating
Upside/ Downside
Action
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Edward Nash | Canaccord Genuity | $615→$612 | buy | 42.81%Upside | Reiterated | 10/29/26 | ||
| Jason Zemansky | Bank of America Securities | $543→$533 | hold | 24.38%Upside | Reiterated | 10/19/26 | ||
| Sadia Rahman | Wells Fargo | $685 | buy | 59.85%Upside | Reiterated | 10/16/26 | ||
| Ashwani Verma | UBS | $669→$735 | buy | 71.52%Upside | Reiterated | 10/15/26 | ||
| Andrew Fein | H.C. Wainwright | $620 | buy | 44.68%Upside | Reiterated | 10/08/26 | ||
| Eliana Merle | Barclays | $962 | buy | 124.49%Upside | Reiterated | 09/30/26 | ||
| Andrea Newkirk | Goldman Sachs | $704 | buy | 64.28%Upside | Initiated | 09/24/26 | ||
| Eric Joseph | Citi | $725 | buy | 69.18%Upside | Initiated | 09/23/26 | ||
| Andy Chen | Wolfe Research | $605 | buy | 41.18%Upside | Upgraded | 08/04/26 | ||
| Srikripa Devarakonda | Truist Financial | $709 | buy | 65.45%Upside | Reiterated | 07/31/26 | ||
 Unknown AnalystNot Ranked | B. Riley Securities | $670 | buy | 56.35%Upside | Initiated | 07/31/26 | ||
| Ritu Baral | TD Cowen | $644 | buy | 50.28%Upside | Reiterated | 07/30/26 | ||
| Jonathan Wolleben | Citizens JMP | $737→$739 | buy | 72.45%Upside | Reiterated | 07/17/26 | ||
| Unknown AnalystNot Ranked | Jefferies | $600 | buy | 40.01%Upside | Reiterated | 06/30/26 | ||
| Yasmeen Rahimi | Piper Sandler | $900 | buy | 110.02%Upside | Reiterated | 06/29/26 |
| Price Target | Follow | Article | ||||||
|---|---|---|---|---|---|---|---|---|
| Edward Nash | 10/29/26 | $615→$612 | buy | 42.81%Upside | Reiterated | Canaccord Genuity | ||
| Jason Zemansky | 10/19/26 | $543→$533 | hold | 24.38%Upside | Reiterated | Bank of America Securities | ||
| Sadia Rahman | 10/16/26 | $685 | buy | 59.85%Upside | Reiterated | Wells Fargo | ||
| Ashwani Verma | 10/15/26 | $669→$735 | buy | 71.52%Upside | Reiterated | UBS | ||
| Andrew Fein | 10/08/26 | $620 | buy | 44.68%Upside | Reiterated | H.C. Wainwright | ||
| Eliana Merle | 09/30/26 | $962 | buy | 124.49%Upside | Reiterated | Barclays | ||
| Andrea Newkirk | 09/24/26 | $704 | buy | 64.28%Upside | Initiated | Goldman Sachs | ||
| Eric Joseph | 09/23/26 | $725 | buy | 69.18%Upside | Initiated | Citi | ||
| Andy Chen | 08/04/26 | $605 | buy | 41.18%Upside | Upgraded | Wolfe Research | ||
| Srikripa Devarakonda | 07/31/26 | $709 | buy | 65.45%Upside | Reiterated | Truist Financial | ||
| Unknown AnalystNot Ranked | 07/31/26 | $670 | buy | 56.35%Upside | Initiated | B. Riley Securities | ||
| Ritu Baral | 07/30/26 | $644 | buy | 50.28%Upside | Reiterated | TD Cowen | ||
| Jonathan Wolleben | 07/17/26 | $737→$739 | buy | 72.45%Upside | Reiterated | Citizens JMP | ||
| Unknown AnalystNot Ranked | 06/30/26 | $600 | buy | 40.01%Upside | Reiterated | Jefferies | ||
| Yasmeen Rahimi | 06/29/26 | $900 | buy | 110.02%Upside | Reiterated | Piper Sandler |
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Best Analysts Covering Madrigal Pharmaceuticals
3 Months
Success Rate10/14 ratings generated profit
71%
Average Return
+10.34%
Copying Yasmeen Rahimi's trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +10.34% per trade.
1 Year
Success Rate17/22 ratings generated profit
77%
Average Return
+60.61%
Copying Jay Olson's trades and holding each position for 1 Year would result in 77.27% of your transactions generating a profit, with an average return of +60.61% per trade.
2 Years
Success Rate30/34 ratings generated profit
88%
Average Return
+95.28%
Copying Jonathan Wolleben's trades and holding each position for 2 Years would result in 88.24% of your transactions generating a profit, with an average return of +95.28% per trade.
0JXI Analyst Recommendation Trends
| Rating | May 26 | Jun 26 | Jul 26 | Aug 26 | Sep 26 |
|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 4 | 4 |
| Buy | 11 | 19 | 12 | 13 | 7 |
| Hold | 3 | 5 | 4 | 3 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 |
| total | 18 | 29 | 21 | 20 | 12 |
In the current month, 0JXI has received 11 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. 0JXI average Analyst price target in the past 3 months is 686.78.
0JXI Financial Forecast
High$-0.10
Consensus$-0.86
Low$-2.00
0JXI Earnings Forecast
Next quarter’s earnings estimate for 0JXI is -$0.86 with a range of -$2.00 to -$0.10. The previous quarter’s EPS was -$1.99. Its overall industry beat the EPS estimate 57.80% of the time in the past 12 months.
High$422M
Consensus$404M
Low$380M
0JXI Sales Forecast
Next quarter’s sales forecast for 0JXI is $404.17M with a range of $380.38M to $421.60M. The previous quarter’s sales results were $364.25M. Its overall industry beat sales estimates 50.04% of the time in the past 12 months.
0JXI Stock Forecast FAQ
What is GB:0JXI’s average 12-month price target, according to analysts?
Based on analyst ratings, Madrigal Pharmaceuticals’s 12-month average price target is $686.78.
What is GB:0JXI’s upside potential, based on the analysts’ average price target?
Madrigal Pharmaceuticals has 60.26% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is Madrigal Pharmaceuticals a Buy, Sell or Hold?
Madrigal Pharmaceuticals has a consensus rating of Strong Buy, which is based on 8 buy ratings, 1 hold ratings and 0 sell ratings.
What is Madrigal Pharmaceuticals’s share price target?
The average share price target for Madrigal Pharmaceuticals is $686.78. This is based on 9 Wall Street analysts’ 12-month price targets, issued in the past 3 months. The highest analyst share price target is $962.00, and the lowest forecast is $533.00. The average share price target represents a 60.26% increase from the current price of $428.53.
What do analysts say about Madrigal Pharmaceuticals?
Madrigal Pharmaceuticals’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Street analysts.
How can I buy shares of Madrigal Pharmaceuticals?
To buy shares of GB:0JXI, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.